AbstractAbstractPTB Reports,2023,9,3,71-72.DOI:10.5530/PTB.2023.9.12Published:December 2023Type:Drug ReviewAuthors:Juman Alsaab Author(s) affiliations:Juman Alsaab, Pharm D, Ministry of Health, Riyadh, SAUDI ARABIA. Abstract:Registrations: It had been registered in the following countries: United States of America (USA), United Kingdom (UK), Canada, and Saudi Arabia (SA.) USA, and Japan. Trade name (USA); VOQUEZNA Registration number (SA); Not available. Insurance Drug Formulary (SA); Not available. General Information: Registered Company: Pathom Pharmaceutics. Regulatory Status: RX. Mechanism of Action: Vonoprazan Potassium-competitive acid blocker (PCAB); inhibition in a potassiumcompetitive manner the H+, K+-ATPase enzyme system. Ampicillin derivative penicillin-binding proteins and cell wall inhibitor. Clarithromycin reversibly binds to the P site of 50S ribosomal subunit as macrolide antimicrobial; and inhibits RNA-dependent protein synthesis by stimulating the peptidyl t-RNA dissociation from ribosomes. Read more... View:PDF (173.94 KB) PDF PDF Images Drug Review: Vonoprazan Slides ‹ Perceptions and Attitudes about the Voluntary/Charitable Pharmaceutical Care Services in Saudi Arabia up Virtual Clinical Pharmacy Services: A New Initiative Project in Saudi Arabia ›